Quest LaboratoriesNSE:QUESTLAB +1.28%52 Equity-to-Asset is 0.87 as of Mar. 2026, which is 118% above its 10-year median of 0.40. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 52/100. The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Quest Laboratories ranks better than 90.56% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Quest Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹968.2 Mil. Quest Laboratories's Total Assets for the quarter that ended in Mar. 2026 was ₹1,111.5 Mil.
Therefore, Quest Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.87.
The historical rank and industry rank for Quest Laboratories's Equity-to-Asset or its related term are showing as below:
NSE:QUESTLAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29 Med: 0.4 Max: 0.87
Current: 0.87
During the past 6 years, the highest Equity to Asset Ratio of Quest Laboratories was 0.87. The lowest was 0.29. And the median was 0.40.
NSE:QUESTLAB's Equity-to-Asset is ranked better than 90.56% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:QUESTLAB: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Quest Laboratories Equity-to-Asset Related Terms
Quest Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Quest Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Quest Laboratories and its competitors. This is 118% above median its historical median of 0.40. Over the past decade, Quest Laboratories' Equity-to-Asset has ranged from 0.29 to 0.87. According to the industry distribution chart, Quest Laboratories ranks #95 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 9.4%.
Is Quest Laboratories' Equity-to-Asset too high?
Quest Laboratories' current Equity-to-Asset of 0.87 is 118% above median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.87. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Quest Laboratories' value of 0.87 is 42.6% above this industry median. Based on the distribution chart, Quest Laboratories ranks #95 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Quest Laboratories has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #95 out of 1006 companies for Equity-to-Asset. This places Quest Laboratories in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Quest Laboratories' value of 0.87 is 42.6% above this benchmark. Historically, Quest Laboratories' own Equity-to-Asset has ranged from 0.29 to 0.87 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.61, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Equity-to-Asset of 0.87 is 42.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Equity-to-Asset is 0.87, which is 118% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 118% above median its 10-year median of 0.40 and 42.6% above the Drug Manufacturers industry median of 0.61. Quest Laboratories' overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
52GF Score
Get the complete analysis for NSE:QUESTLAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
